Frequently Asked Questions

EpicOncology™ Data Platform and Epiphany Consulting FAQ

General EpicOncology™ questions

What countries are available within the EpicOncology™ platform?

Our extensive country coverage includes:


  • U.S.
  • Argentina
  • Brazil, with special breakouts for Brazil Rural and Brazil Urban
  • Columbia (2020)
  • Canada
  • Mexico


  • France
  • Germany
  • Italy
  • Spain
  • U.K.
  • Denmark (2020)
  • Finland (2020)
  • Netherlands
  • Norway (2020)
  • Poland
  • Russian Federation
  • Sweden (2020)
  • Turkey


  • Japan
  • Australia
  • China, with separate breakouts for China Rural, China Urban and China SAR (Special Administrative Regions which includes Hong Kong and Macao)
  • India
  • South Korea
  • Taiwan

NOTE: The countries and cancers listed are specific to Epic; we are able to provide data for other countries/cancers via custom project.

What cancers are available within the EpicOncology™ platform?

Over 55 cancers (including 110+ sub-types /biomarkers) are available in to EpicOncology™:


  • Biliary Tract
  • Bladder (and other urothelial cancers)
  • Brain
  • Breast
  • Cervical
  • Colorectal (Colon, Rectal)
  • Esophageal
  • Gastric
  • Gastrointestinal Stromal Tumors (GIST)
  • Head & Neck Cancer (Larynx, Oral Cavity, Oropharynx, Hypopharynx, Nasopharynx, Nasal Cavity & Sinus)
  • Liver
  • Lung (Non-small cell and Small cell)
  • Melanoma
  • Mesothelioma
  • Ovarian (with fallopian tube and primary peritoneal)
  • Pancreatic
  • Prostate
  • Renal cell (kidney)
  • Osteosarcoma
  • Soft Tissue Sarcoma
  • Thyroid


  • Leukemia, Acute Lymphocytic (ALL)
  • Leukemia, Acute Myeloid Lymphocytic (AML)
  • Leukemia, Chronic Lymphocytic (CLL)
  • Leukemia, Chronic Myelogenous (CML)
  • Lymphoma, Hodgkin
  • Lymphoma, Non-Hodgkin’s (NHL)
  • Multiple Myeloma
  • Myelodysplastic Syndromes (MDS)
  • Myeloproliferative Neoplasms (MPN)

What types of subscriptions do you offer?

We offer a variety of options to meet the specific needs of our clients, ranging from global access to all countries and cancers covered in EpicOncology™ to access for specific countries, cancers, and analyses.

Do you offer a trial subscription?

We offer prospective clients the chance to evaluate EpicOncology™ data and online interface within a complimentary, limited access trial period. Please contact us for full details.

Is access to EpicOncology™ limited by the number of users, or a geographic region or country?

Access to EpicOncology™ is valid for all employees of the client and includes any updates to the database throughout the subscription period.

What statistics are available in EpicOncology™?

We present analyses data in a series of tables you can filter for stage, subtype, gender and age group. Main groupings include:

  • Basic statistics;
  • Advanced statistics which are generated using Epiphany’s flow model;
  • Available estimates, providing perspectives on the number of patients in specific “eligible groups”;
  • Treated patient estimates, providing estimates of the number of patients receiving specific types of therapeutic interventions;
  • Special populations, generated to provide additional insight into specific cancer sites and subtypes

Is the framework of your model flexible enough to allow for substitution of our own data?

The EpicOncology™ system has the unique ability to generate specific epidemiology datasets (made available only to the client) within the EpicOncology™ interface.

Common Definitions

Course of Therapy

A sequential treatment by any modality (i.e., surgery, radiation, and/or drug therapy); for example, first course therapy is the first time that a patient is treated, regardless of the type of treatment.

Line of Therapy

A sequential treatment within a specific modality; for example, second-line drug therapy refers to the second time that a patient receives drug therapy, though a patient might have initially been treated with surgery only, then later drug therapy (which would be 1L drug), and again drug therapy (2L drug therapy in the third-course setting).


Return of disease following a response, which could be a CR or PR; to relapse, patients must have been prior responders who survive over time, until the disease returns/relapses; it is a prevalent-based population capturing patients from prior years.


To be clear in our definitions, Epiphany refrains from using this term in our modeling. However, when used by industry to refer to patient populations, we have found that the term generally refers to relapsed disease (as defined by Epiphany) plus refractory (i.e., non-responding) patients, as usually the goal is to capture the complete pool of patients eligible for subsequent therapies. Epiphany’s model assesses both relapsed and refractory patients for possible progression. Including the refractory patients in a definition of recurrence captures all progressing patients in the definition as well.


Epiphany’s models do not use this term. In discussions, it can refer to either modality/modalities or drugs, depending on the context.


Progression refers to progression to subsequent stages of disease. In Epiphany’s models, we separate the concepts (and associated calculations) for relapse and progression. Not all patients who relapse then progress; for example, some patients may relapse in the same stage in which they received diagnosis. Metastatic patients cannot “progress” since they are already metastatic. Also, do not use the term “progression” to apply to progression between lines of therapy, as sometimes done in the industry. (Sometimes we even write out “progression-to-subsequent-stage” to clarify the concept.)


What sources are used to generate the data in EpicOncology™?

Epiphany relies on leading, publicly available cancer registries as well as registry-based datasets and secondary publications. These include:

  • Populations: United Nations Population Division: The 2015 Revision, U.S. Census Bureau Projections
  • Mortality: WHO Mortality Databank, U.S. National Center for Health Statistics (NCHS)
  • Survival:
    • U.S.: SEER database (18 registry data, period analysis)
    • Japan: National Cancer Center (NCC)
    • Europe: EUROCARE-3, -4, and -5, and country-specific registry data
    • Taiwan: Taiwan Cancer Registry
    • Global: CONCORD-1, -2, and -3 survival studies

Support Service for EpicOncology

What is Epiphany’s service promise?

Our promise is to provide clients with a response to, or acknowledgement of, a question within 24 hours.

What support services does a subscription to EpicOncology™ include?

Epiphany’s focus on client service is one of our primary differentiators in today’s marketplace and includes:

  • Unlimited email and telephone inquiries
  • Monthly teleconferences
  • Web-conference and on-site training sessions
  • On-site meetings and consultations

Questions About Epiphany Partners

Do you do custom consulting projects?

Yes! We offer an array of custom consulting services including specialized models based on to EpicOncology™ as well as detailed analytical support in cancer and other diseases that are not currently available in the interface. We also conduct epidemiology research, develop patient and product forecasts, and provide regulatory/HEOR support, among other related services.

Examples of projects we have completed for clients include:

  • Patient forecasts accounting for the impact of new agents/modalities
  • Forecasting of specifically-defined subsets including detailed biomarker populations
  • Generating client-specific epidemiology datasets within the EpicOncology™ interface
  • Support of international orphan drug applications
  • Development of client-defined patient flow diagrams

Does Epiphany collaborate with clients on generating commercial forecasts for new products, using epidemiology as a starting point?

Yes! Epiphany has the forecasting expertise and integrated systems to generate client specific epidemiology datasets within the EpicOncology™ interface.

Do you offer training for various topics such as biomarkers, disease and treatment staging, cancer diagnostics, immunotherapy, etc.?

Yes. Epiphany offers specialized training and presentations across a range of topics that we can deliver onsite or via webinar.

Leverage the Insights in EpicOncology™ for Your Research Projects

It’s time to change how you see cancer. Start your EpicOncology™ subscription by contacting Epiphany today.